Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net cash (used in) provided by operating activities | (60,582) | 131,827 |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (9,853) | (19,016) |
| Purchases of property and equipment | (353) | (152) |
| Proceeds from maturity of marketable securities | 60,900 | 32,800 |
| Net cash used in investing activities | 50,694 | 13,632 |
| Cash flows from financing activities: | ||
| Proceeds from Employee Stock Purchase Plan | 465 | 370 |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s capex?
- Stoke Therapeutics, Inc. (STOK) reported capex of $353K in Q1 2026.
- How has Stoke Therapeutics, Inc.'s capex changed year-over-year?
- Stoke Therapeutics, Inc.'s capex increased by 132.2% year-over-year, from $152K to $353K.
- What is the long-term trend for Stoke Therapeutics, Inc.'s capex?
- Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s capex has grown at a -13.6% compound annual growth rate (CAGR), from $1.2M to $670K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Stoke Therapeutics, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude